Memantine is an inhibitor of NMDA receptors, which are pathologically activated by excessive concentrations of glutamate in the synaptic cleft in Alzheimer's disease. It is indicated in the treatment of moderate to severe cases of Alzheimer's disease, often in combination with acetylcholinesterase inhibitors. At the experimental level, its administration shows a number of promising effects, including an impact on diabetes associated with the development of neurodegenerative diseases.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
